Menu Back toSession-3-FDAA-Final-Rule-Latest-Updates-from-ClinicalTrials-gov

Clinical Trial Disclosure and Data Transparency Conference

Learn about the latest requirements in clinical trial disclosure and data transparency, share best practices, and engage in in-depth discussions on hot topics.


Session 3: FDAAA Final Rule: Latest Updates from ClinicalTrials.gov

Session Chair(s)

Robert  Paarlberg, MS, MSc

Robert Paarlberg, MS, MSc

  • Principal
  • Paarlberg & Associates LLC, United States
The Final Rule expanding the registry and results data bank specified in Title VIII of the Food and Drug Administration Amendments Act of 2007 (FDAAA) was published in the Federal Register on September 21, 2016. The Final Rule had an effective date of January 18, 2017 and a compliance date of April 18, 2017. This session will provide the latest update from NLM on the Final Rule including how the new requirements for results reporting.
Learning Objective :
  • Describe the requirements to report results under the Final Rule
  • Recognize how the Final Rule is impacting current processes
  • Explain how NLM is interpreting the Final Rule requirements
  • Speaker(s)

    Rebecca  Williams, PharmD, MPH

    Speaker

    Rebecca Williams, PharmD, MPH

    • Acting Director, ClinicalTrials.gov, NCBI
    • National Library of Medicine, NIH, United States

    Contact us

    Customer Service

    1.888.257.6457


    Short Course 1

    Disclosures 101


    Short Course 2

    Preparing Documents for Disclosure and Public Sharing 


    DIA's Clinical Trial Content Toolkit

    View Here